الفهرس 
Title
AbstractOnly 14 pages are availabe for public view
 |  | from | 167 |  |  |
| | | from | 167 | | |
Abstract
Background:Follicular lymphoma (FL), commonly referred to as an indolent lymphoma, is the second most common type of non-Hodgkin lymphoma. Median survival rates have historically reported to be in the range of 8 to 10 years. Mantle cell lymphoma (MCL) is an uncommon B-cell malignancy subtype that was officially classified as a distinct class of non-Hodgkin lymphoma. Epidemiological risk factors are incompletely defined, with data to suggest both inherited and exogenous triggers related to the development of this malignancy. Aim of the study: to assess clinical prognostic factors and survival outcome for all patients with Mantle Cell Lymphoma and Low-Grade Follicular presented to the National Cancer Institute between the periods of January 2008 to December 2016. Patients and methods: our retrospective study included 85 patients pathologically proven to be low grade follicular NHL and 26 patients pathologically proven to be Mantle cell lymphoma. Result: among 85 patients pathologically proven to be low grade follicular NHL showed median age 53 years (range 28 to 85years) with female predominance Ann Arbor stage IV is the most encountered stage.Complete response is achieved in 38.8% of the patients. Median follow up period is 14.3 months & median PFS is 10.8 months